According to TipRanks, in a report published on Thursday, Cowen begins coverage on Roche Holdings AG Basel shares. On the stock, the company issued a buy rating and a target price of $48.00.
On the other hand, in a research note released on Monday, the 23rd of December, the Royal Bank of Canada reissued a rating of ‘outperform’ on Roche Holdings AG Basel shares. The stock has been issued a rating of ‘sell’ by one equities research analyst, it has been issued a rating of ‘hold’ by 2 equities research analysts, whereas 6 equities research analysts have issued the firm’s stock with a rating of ‘buy’.
The consensus rating for the firm is ‘Buy’, whereas its average target price is $42.50.
On Thursday, Roche Holdings AG Basel opened at $41.20. The company holds a $290.31-billion market capitalization. Its P/E ratio stands at 17.76, its PEG ratio is 2.49, and the company has a beta of 0.50. The company supports a 1-year low of $31.81 and supports a 1-year high of $42.88. Roche Holdings AG Basel’s fifty-day moving average price and 200-day moving average price are $40.28 and $36.83 respectively.
Multiple huge investors have lately increased or lessened their stakes in Roche Holdings AG Basel. Lenox Wealth Advisors LLC increased, by 227.6%, its shares in the company during the Q3. It now is an owner to 1,127 shares of Roche Holdings AG Basel’s stock. These shares are valued at a total of $41,000 following the purchase of 783 additional shares during the Q3.
Winthrop Partners WNY LLC has obtained a new stake in Roche Holdings AG Basel during the Q3. This is valued at a total of $102,000.
FNY Investment Advisers LLC has obtained a new stake in Roche Holdings AG Basel during the Q3. This is valued at a total of $182,000.